Sulfisoxazole

Sulfisoxazole

SCHEMBL788644

Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C.Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfisoxazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 13/20 1.00
EDNRB P24530 9/20 1.00
MEN1 O00255 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
CYP2C19 P33261 1/20 1.00
ADRA1A P35348 1/20 1.00
KMT2A Q03164 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfisoxazole SCHEMBL23467 1.00 EDNRA (1.00) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL5917298 0.98 EDNRA (0.97) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL2200933 0.98 EDNRA (0.97) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL5959142 0.96 EDNRA (0.92) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL16097888 0.94 EDNRA (0.89) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL3221114 0.91 EDNRA (0.82) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL20770061 0.90 EDNRA (0.81) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL4973236 0.90 EDNRA (0.81) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL28264710 0.90 EDNRA (0.81) EDNRAEDNRBMEN1CYP2C9TSHR
Sulfisoxazole SCHEMBL887764 0.89 EDNRA (0.79) EDNRAEDNRBMEN1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3185859-A1 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE Pharnext (FR) 2017-07-05 EP disclosed
EP-3038614-A1 COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS Pharnext (FR) 2016-07-06 EP disclosed
WO-2016030522-A1 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE PHARNEXT (FR) 2016-03-03 WO disclosed
EP-2892519-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE Pharnext (FR) 2015-07-15 EP disclosed
WO-2015028659-A1 COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS PHARNEXT (FR) 2015-03-05 WO disclosed
EP-2819663-A1 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE Pharnext (FR) 2015-01-07 EP disclosed
WO-2014037412-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE PHARNEXT (FR) 2014-03-13 WO disclosed
WO-2013127918-A1 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE PHARNEXT (FR) 2013-09-06 WO disclosed
EP-2616484-A2 SCREENING METHOD Universiteit Leiden (NL) 2013-07-24 EP disclosed
EP-2560631-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS Pharnext (FR) 2013-02-27 EP disclosed
EP-2496226-A1 NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE Pharnext (FR) 2012-09-12 EP disclosed
WO-2012117075-A2 TREATMENT OF CEREBRAL ISCHEMIA PHARNEXT (FR) 2012-09-07 WO disclosed
WO-2012117076-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS PHARNEXT (FR) 2012-09-07 WO disclosed
WO-2012035120-A2 SCREENING METHOD UNIVERSITEIT LEIDEN (NL) 2012-03-22 WO disclosed
WO-2011054759-A1 NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE PHARNEXT (FR) 2011-05-12 WO disclosed